Escherichia coli antimicrobial susceptibility profile and cumulative antibiogram to guide empirical treatment of uncomplicated urinary tract infections in women in the province of Québec, 2010-15.

OBJECTIVES Empirical treatment of uncomplicated urinary tract infections (UTIs) in women should be based on local susceptibility data. We aimed to generate regional and provincial cumulative antibiograms combining data from different laboratory information systems and determine the impact of basic patient characteristics on susceptibility results. METHODS All positive urine samples for Escherichia coli obtained from women aged 18-65 years old in outpatient settings between 1 April 2010 and 31 March 2015 from four hospitals in Quebec, Canada, were included. The cumulative antibiogram for ciprofloxacin, nitrofurantoin and trimethoprim/sulfamethoxazole was calculated. A clinically significant difference in susceptibility profile was defined as factor(s) that lowered the susceptibility proportion below 80%. RESULTS A total of 36 293 positive urine cultures were analysed. In the last year of the study, the proportion of susceptibility for ciprofloxacin, nitrofurantoin and trimethoprim/sulfamethoxazole was 90.3%, 95.4% and 81.9%, respectively. The susceptibility proportion was <80% for trimethoprim/sulfamethoxazole in the Montreal region (73.4%; 95% CI 71.1%-75.9%), whereas it remained >80% for the other regions. A significant decrease in susceptibility with time was identified for ciprofloxacin (92.1%-90.3%, P < 0.001) and nitrofurantoin (97.1%-95.4%, P < 0.001). Increasing age, recent hospitalization and site of collection were associated with an increase in resistance for certain antibiotics. CONCLUSIONS Overall, all first-line antimicrobials remain acceptable choices for empirical treatment of uncomplicated UTIs in women in Quebec. The regional variability in susceptibility data within a single province emphasizes the importance of local susceptibility data to inform the development of empirical treatment guidelines for UTIs.

[1]  N. Lawrentschuk,et al.  Extended-spectrum beta-lactamase-producing Enterobacteriaceae in hospital urinary tract infections: incidence and antibiotic susceptibility profile over 9 years , 2016, World Journal of Urology.

[2]  A. Babiker,et al.  Antibiotic Resistance among Urinary Isolates from Female Outpatients in the United States in 2003 and 2012 , 2016, Antimicrobial Agents and Chemotherapy.

[3]  S. Geerlings,et al.  Febrile urinary tract infections: pyelonephritis and urosepsis , 2016, Current opinion in infectious diseases.

[4]  M. Kumar,et al.  Risk Factor Analysis in Clinical Isolates of ESBL and MBL (Including NDM-1) Producing Escherichia coli and Klebsiella Species in a Tertiary Care Hospital. , 2015, Journal of clinical and diagnostic research : JCDR.

[5]  N. Woodford,et al.  Surveillance of antibiotic susceptibility of urinary tract pathogens for a population of 5.6 million over 4 years. , 2015, The Journal of antimicrobial chemotherapy.

[6]  S. Hultgren,et al.  Urinary tract infections: epidemiology, mechanisms of infection and treatment options , 2015, Nature Reviews Microbiology.

[7]  Chien-Chang Lee,et al.  Comparative Effectiveness of Different Oral Antibiotics Regimens for Treatment of Urinary Tract Infection in Outpatients: An Analysis of National Representative Claims Database , 2014, Medicine.

[8]  H. Kiyota,et al.  Epidemiology, treatment and prevention of healthcare-associated urinary tract infections , 2012, World Journal of Urology.

[9]  K. Mühlemann,et al.  Determinants of Quinolone versus Trimethoprim-Sulfamethoxazole Use for Outpatient Urinary Tract Infection , 2012, Antimicrobial Agents and Chemotherapy.

[10]  Richard Colgan,et al.  International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[11]  D. Low,et al.  Antibiotic resistance in Escherichia coli outpatient urinary isolates: final results from the North American Urinary Tract Infection Collaborative Alliance (NAUTICA). , 2006, International journal of antimicrobial agents.

[12]  Peter A M Anderson,et al.  Uncomplicated urinary tract infection in women. Current practice and the effect of antibiotic resistance on empiric treatment. , 2006, Canadian family physician Medecin de famille canadien.

[13]  L. Nicolle,et al.  Antibiotic resistance in outpatient urinary isolates: final results from the North American Urinary Tract Infection Collaborative Alliance (NAUTICA). , 2005, International journal of antimicrobial agents.

[14]  J. Rodríguez-Baño,et al.  Epidemiology and Clinical Features of Infections Caused by Extended-Spectrum Beta-Lactamase-Producing Escherichia coli in Nonhospitalized Patients , 2004, Journal of Clinical Microbiology.

[15]  C. C. McOsker,et al.  Nitrofurantoin: mechanism of action and implications for resistance development in common uropathogens. , 1994, The Journal of antimicrobial chemotherapy.

[16]  A. Bergman.  Urinary tract infections in women , 1991, Current opinion in obstetrics & gynecology.

[17]  G. Kahlmeter.  An international survey of the antimicrobial susceptibility of pathogens from uncomplicated urinary tract infections: the ECO.SENS Project. , 2003, The Journal of antimicrobial chemotherapy.